This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

CLAIMS

1. A compound of Formula (IA):



(IA)

wherein:

a is 0 and b is 0;

or a is 1 and b is 0;

or a is 1 and b is 1;

Y is selected from N and N→O;

one of R_1, R_2 and R_3 is a ring moiety selected from C_{4-6} cycloalkyl, phenyl, naphthyl, C_{1-5} heterocyclyl, (C_{4-6} cycloalkyl)C_{1-3} alkylene, (phenyl)C_{1-3} alkylene, (naphthyl) C_{1-3} alkylene, and (C_{1-5} heterocyclyl)C_{1-3} alkylene;

and the remaining two of R_1, R_2 and R_3 are independently selected from hydrogen, halogen, and C_{1-6} alkyl;

wherein said ring moiety is substituted with a moiety of formula:

-X-W-Z, X-Z, W-Z or Z;

wherein X is selected from the group consisting of O, S, SO_2, SO, NR_4, -CH=CH-, —C≡C—, -OCH_2-C≡C-, -C≡C-CH_2O-, -$CH(R_5)$-, CO, -O-CO-, -CO-O-, CHOH, -NR_4-CO-, -CO-NR_4-, -SO_2-NH-, -NR_4-SO_2-, and -SO_2-NR_4-; R_4 is H, or C_{1-6} alkyl; R_5 is H, C_{1-6} alkyl, or hydroxy;

W is C_{1-6} alkylene, phenylene, (phenylene)(C_{1-3} alkylene), or -CH_2-CHCH-CH_2-;

Z is selected from:

(i) $NR_{21}R_{22}$, $NHCOR_{23}$, or $NHSO_2R_{23}$,

(ii) C_{3-6} heterocyclyl or C_{7-12} fused bicyclyl, and

(iii) phenyl substituted with a C_{3-6} heterocyclyl group, or with a (C_{3-6} heterocyclyl)C_{1-6} alkylene group,

wherein each phenyl or heterocyclyl group in (ii) or (iii) may be substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyclohexyl, cyclohexenyl, phenyl, (phenyl)C_{1-6} alkylene, trihalo C_{1-6} alkyl, nitro, SCH_3, $NR_{21}R_{22}$, amido, amidino, amino C_{1-6} alkyl, acetylene, $CHR_{23}R_{24}$, COR_{23}, acetyl, $NHCOCH_3$, C_{3-6} heterocyclyl, (C_{3-6} heterocyclyl) C_{1-6} alkylene, cyano, $NHSO_2CH_3$, $N(SO_2CH_3)_2$, carboxy, C_{1-6} alkoxycarbonyl, amidoxime, trihalo C_{1-6} alkoxy, oxo, hydroxyiminomethyl, C_{1-6} alkylcarboxy, carboxy C_{1-6} alkyl, trihaloacetyl, and methylsulfonyl;

wherein each of R_{21} and R_{22} is independently selected from H, C_{1-6} alkyl, C_{4-7} cycloalkyl, phenyl, benzyl, C_{1-6} alkoxy, hydroxy, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{2-8} acyl, C_{1-8} alkylsulfonyl;

R_{23} is C_{1-6} alkyl, C_{4-7} cycloalkyl, phenyl, benzyl, C_{1-6} alkoxy, hydroxy, aryl, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{2-8} acyl, C_{1-8} alkylsulfonyl;

R_{24} is H, halogen, hydroxy, amino, C_{1-6} alkyl, C_{4-7} cycloalkyl, phenyl, or benzyl;

in addition, said R_1, R_2 or R_3 that is a ring moiety is optionally substituted with between 1 and 3 substituents Q_1, Q_2, and Q_3, which, if present, are independently selected from: R_{25}, $NR_{26}R_{27}$, $NHCOR_{28}$, $NHSOR_{29}$, and $NHSO_2R_{30}$;

wherein R_{25} is H, C_{1-6} alkyl, C_{4-7} cycloalkyl, phenyl, benzyl, C_{1-6} alkoxy, hydroxy, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{2-8} acyl, or C_{1-8} alkylsulfonyl;

wherein each of R_{26} and R_{27} is independently selected from H, C_{1-6} alkyl, C_{4-7} cycloalkyl, phenyl, benzyl, C_{1-6} alkoxy, hydroxy, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{2-8} acyl, C_{1-8} alkylsulfonyl;

each of R_{28}, R_{29}, and R_{30} is C_{1-6} alkyl, C_{4-7} cycloalkyl, phenyl, benzyl, C_{1-6} alkoxy, hydroxy, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{2-8} acyl, C_{1-8} alkylsulfonyl;

and

R_{11}, R_{12}, R_{14} and R_{15} are each independently selected from hydrogen, halogen, C_{1-6} alkyl and C_{1-6} alkoxy;

R_{13} is selected from hydrogen, oxo, and phenyl;

R_{16} is selected from hydrogen, cyano, C_{1-6} alkyl, and C_{1-6} alkylamino;

wherein each of the above carbocyclyl and heterocarbocyclyls can be optionally substituted with between 1 and 3 substituents selected from C_{1-4} alkyl, hydroxy, amino, halo, C_{1-4} alkoxy, $CONH_2$, phenyl, and C_{1-4} alkylamino, di(C_{1-4})alkylamino;

and wherein –X-W-Z is not [4-(imidazol-1yl)-phenyl]oxy where a is 1 and b is 0;

or a pharmaceutically acceptable salt, ester, or amide thereof.

2. The compound of claim 1, wherein Y is N.

3. The compound of claim 1, wherein a is 1 and b is 0.

4. The compound of claim 1, wherein a is 0 and b is 0.

5. The compound of claim 1, wherein a is 1 and b is 1.

6. The compound of claim 1, wherein at least two of R_{11}, R_{12}, R_{13}, and R_{16} are H.

7. The compound of claim 1, wherein, if present, R_{14} and R_{15} are H.

8. The compound of claim 1, wherein one of R_1 and R_2 is a substituted ring.

9. The compound of claim 1, wherein R_1 is a substituted ring.

10. The compound of claim 1, wherein R_2 is a substituted ring.

11. The compound of claim 1, wherein one of R_1 and R_2 is a substituted phenyl or substituted pyridyl; and the other two of R_1, R_2 and R_3 are independently selected from hydrogen, halogen, and C_{1-6} alkyl; wherein the substituent on said substituted phenyl or pyridyl is a para- or meta- substituent.

12. The compound of claim 1, wherein the substituent on said ring is of formula: X-Z or X-(C_{1-6} alkylene)-Z, wherein X is selected from the group consisting of of O, S, NR_{21}, $-OCH_2-C\equiv C-$, $-NR_{21}-CO-$, $-CO-NR_{21}-$, $-NH-SO_2-$, $-SO_2-NH-$, $-NR_{23}-SO_2-$, and $-SO_2-NR_{23}$; and Z is selected from (i) $NR_{21}R_{22}$ and pyridyl, piperidyl, and pyrrolidyl, optionally substituted.

13. The compound of claim 1, wherein a is 1 and b is 0; Y is N; one of R_1 and R_2 is phenyl para-substituted with X-W-Z, wherein X is O, NH, N(C_{1-3} alkyl), NHCO, $NHSO_2$, or S; and W is C_{2-5} alkylene.

14. The compound of claim 13, wherein Z is piperidyl or pyrrolidyl, optionally substituted with methyl, $CONH_2$, or phenyl.

15. The compound of claim 14, wherein R_{11}, R_{12}, R_{13}, and R_3 are each H.

16. The compound of claim 1, wherein each of R_3, R_{11}, R_{12}, and R_{13} is H, halo, methyl, or methoxy.

17. The compound of claim 1, wherein the R_1, R_2, or R_3 that is a ring moiety is substituted with a moiety of formula –X-W-Z, -X-Z, or –W-Z.

18. The compound of claim 1, selected from
(S, S)-3-(4-(3-Piperidinylpropoxy)phenyl)octahydroindolizine;
(R, R)-3-(4-(3-Piperidinylpropoxy)phenyl)octahydroindolizine;

trans-3-(4-(3-Piperidinylpropoxy)phenyl)octahydroindolizine;
anti-2-(4-(3-Piperidinylpropoxy)phenyl)octahydroindolizine;
syn-2-[4-(3-Piperidinylpropanoxy)phenyl]octahydroindolizine;
3-[4-(Piperidinylpropoxy)phenyl]hexahydro-1H-pyrrolizine;
5-[4-(4-Piperidinylbutoxy)phenyl]indolizine;
trans-3-[4-(N-5-Piperidylpentylamino)phenyl]octahydroindolizine;
5-[4-(3-Piperidinylpropoxy)phenyl]octahydroindolizine;
5-[4-(4-Piperidinylpentanoxy)phenyl]octahydroindolizine;
N-Methyl-N-[4-(*trans*-Octahydro-3-indolizinyl)phenyl]-3-piperidinylpropenamide;
trans-3-[4-(*N*-3-Piperidylpropylamino)phenyl]octahydroindolizine; *trans*-3-[4-(3-Piperidinylmethylpropargyloxy)phenyl]octahydroindolizine;
trans-3-[4-(*N*-5-Piperidylpentanamido)phenyl]octahydroindolizine;
trans-3-{4-[2,2'-(*N*-Methylpyrrolidinyl)ethoxy]phenyl}octahydroindolizine;
anti-2-[3-(3-Piperidinylpropyloxy)phenyl]octahydroindolizine;
trans-3-[4-(N-4-Piperidylbutanamido)phenyl]octahydroindolizine;
trans-3-[4-(*N*-Methyl-*N*-3-piperidylpropylamino)phenyl]octahydroindolizine;
trans-3-[4-(3-Piperidylsulfonylamino)phenyl]octahydroindolizine;
5-[4-(2-Piperidinylethanoxy)phenyl]octahydroindolizine;
trans-3-{4-[2,2'-(*N*-Methylpiperidinyl)ethoxy]phenyl}octahydroindolizine;
tran-3-[4-(4-Methylaminophenylthio)phenyl]octahydroindolizine;
trans-3-[4-(N-Methyl-*N*-5-piperidylpentylamino)phenyl]octahydroindolizine;
3-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-octahydro-indolizine;
Dimethyl-{3-[4-(octahydro-indolizin-3-yl)-phenoxy]-propyl}-amine;
trans-3-[4-(N-3-Piperidinylpropanamido)phenyl]octahydroindolizine;
trans-3-{4-[(2-Piperidylethyl)sulfonyl]amidophenyl}octahydroindolizine;
trans-3-{4-[(2-Piperidylethyl)sulfonyl-N-methylamino]phenyl}octahydroindolizine; and
tran-3-[4-(4-Carboxylicphenylthio)phenyl]octahydroindolizine.

19. The compound of claim 1, selected from:
trans-3-[4-((4-Amidoxime)phenylthio)phenyl]octahydroindolizine;
trans-3-[4-(4-Methansulfonaminophenoxy)phenyl]octahydroindolizine;
trans-3-{4-[2,2'-(*N*-Trifluoroethylpiperidinyl)ethoxy]phenyl}octahydroindolizine;

trans-3-{4-[2,2'-(1-*tert*-Butylcarboxylatepiperidinyl)ethoxy]phenyl}-octahydroindolizine;
trans-3-[4-(3-Piperidylsulfonyl-N-methylamino)phenyl]octahydroindolizine;
trans-3-[4-(4-Aminophenylthio)phenyl]octahydroindolizine;
trans-3-[4-(*N*-Methyl-N-5-piperidylpentanamido)phenyl]octahydroindolizine;
Octahydro-3-[4-(4-pyridinylthio)phenyl]indolizine;
trans-3-[4-(*N*-Phenyl-1-piperazinylmethyl)phenyl]octahydroindolizine;
trans-3-[4-(4-Pyridinylethenyl)phenyl]octahydroindolizine;
trans-3-{4-[2,2'-(*N*-Trifluoroacetylpiperidinyl)ethoxy]phenyl}octahydroindolizine;
tran-3-[4-(3-(2-Dimethylaminoethyl)amino)phenyl]octahydroindolizine;
trans-3-[4-(4-Pyridyloxy)phenyl]octahydroindolizine;
trans-3-{4-[2,2'-(*N*-Amidinopiperidinyl)ethoxy]phenyl}octahydroindolizine;
trans-3-[4-(4-Pyridylmethan-1-ol)phenyl]octahydroindolizine;
trans-3-[4-(2,2'-piperidinylethoxy)phenyl]octahydroindolizine;
4-[4-(Octahydro-indolizin-3-yl)-phenoxy]-quinazoline;
trans-3-[4-(N-Methylsulfonyl)piperidinylamino)phenyl]octahydroindolizine;
trans-3-[4-(3-bis-Methansulfonaminobenzyloxy)phenyl]octahydroindolizine;
3-(4-Thiophen-2-yl-phenyl)-octahydro-indolizine;
trans-3-[4-(*N*-Methylsulfonyl-4-aminopiperidine)phenyl]octahydroindolizine;
4-[4-(4-Pyridylthio)phenyl]octahydoquinolizine;
trans-3-[4-(3-Methansulfonaminobenzyloxy)phenyl]octahydroindolizine; and
trans-3-[4-(4-Trifluromethoxyphenyl)phenyl]octahydroindolizine .

20. The compound of claim 1, selected from:
3-Biphenyl-4-yl-octahydro-indolizine;
trans-3-(4-Phenoxy-phenyl)-octahydro-indolizine;
cis-3-(4-Phenoxy-phenyl)-octahydro-indolizine;
Dimethyl-[5-(octahydro-indolizin-3-yl)-naphthalen-1-yl]-amine;
[4-(Octahydro-indolizin-3-yl)-phenyl]-diphenyl-amine;
5-[4-(4-Pyridinylthio)phenyl]octahydroindolizine;
5-[4-(4-Nitrophenylthio)phenyl]octahydroindolizine;
3-[4-(Pyridin-3-yloxy)-phenyl]-octahydro-indolizine;
2-[4-(Octahydro-indolizin-3-yl)-phenoxy]-1H-benzoimidazole;

3-[4-(4-Nitro-phenylsulfanyl)-phenyl]-octahydro-indolizine;
3-[4-(Pyrimidin-2-ylsulfanyl)-phenyl]-octahydro-indolizine;
2-[4-(Octahydro-indolizin-3-yl)-phenylsulfanyl]-3H-quinazolin-4-one;
2-[4-(Octahydro-indolizin-3-yl)-phenoxy]-quinoline;
2-Methyl-8-[4-(octahydro-indolizin-3-yl)-phenoxy]-quinoline;
4-[4-(Octahydro-indolizin-3-yl)-phenylsulfanyl]-benzonitrile;
5-(4-(4-Aminophenylthio)phenyl)octahydroindolizine;
3-Methylamino-3-(4-bromophenyl)octahydroindolizine;
trans-3-[4-(4-Methylene-1,3-thiazolidine-2,4-diimine)phenyl]octahydroindolizine;
4'-(Octahydro-indolizin-3-yl)-biphenyl-3-ylamine;
3-(4-Thiophen-3-yl-phenyl)-octahydro-indolizine;
2-[4-(Octahydro-indolizin-3-yl)-phenyl]-thiophene-3-carbaldehyde;
4'-(Octahydro-indolizin-3-yl)-biphenyl-4-carbaldehyde;
3-(4'-Fluoro-biphenyl-4-yl)-octahydro-indolizine; and
trans-3-[4-(3-hydroxyiminomethylthienyl)phenyl]octahydroindolizine.

21. The compound of claim 1, selected from:
trans-3-[4-(3-Methylsulfonylaminophenyl)phenyl]octahydroindolizine;
anti-2-[2-(3-Piperidinylpropoxy)phenyl]octahydroindolizine;
trans-3-[4-(4-Aminophenoxy)phenyl]octahydroindolizine;
trans-3-(4-Aminophenyl)octahydroindolizine;
trans-3-(4-(N,N-Dimethylamino)phenyl)octahydroindolizine;
trans-3-(4-(Methylsulfonylamino)phenyl)octahydroindolizine;
trans-3-(4-(bis-Methylsulfonylamino)phenyl)octahydroindolizine;
trans-3-{4-[4-(*N*-(1,1-dimethylethoxycarbonyl)piperidinylamino]phenyl}octahydroindolizine;
trans-3-[4-(4-Piperidinylamino)phenyl]octahydroindolizine;
trans-3-[4-(*N*-Ethyl-N-4-N-methylsufonylpiperidinylamino)phenyl]octahydroindolizine;
N-[4-(*trans*-Octahydro-3-indolizinyl)phenyl]propenamide;
N-Methyl-N-[4-(*trans*-Octahydro-3-indolizinyl)phenyl]propenamide; and
trans-3-{4-[(2-Pyrrolidylethyl)sulfonylamino]phenyl}octahydroindolizine.

22. The compound of claim 1, selected from:
trans-3-{4-[(4-Chlorophenyl)methan-1-ol]phenyl}octahydroindolizine;
trans-3-{4-[(4-Chlorobenzyl]phenyl}octahydroindolizine;
[4-(Octahydro-indolizin-3-yl)-phenyl]-pyridin-3-ylmethyl-amine;
[4-(Octahydro-indolizin-3-yl)-phenyl]-pyridin-2-ylmethyl-amine;
[4-(Octahydro-indolizin-3-yl)-phenyl]-thiophen-3-ylmethyl-amine;
Furan-2-ylmethyl-[4-(octahydro-indolizin-3-yl)-phenyl]-amine;
[4-(Octahydro-indolizin-3-yl)-phenyl]-pyridin-4-ylmethyl-amine;
Benzyl-[4-(octahydro-indolizin-3-yl)-phenyl]-amine;
[4-(Octahydro-indolizin-3-yl)-phenyl]-(1-oxy-pyridin-4-ylmethyl)-amine;
(1H-Imidazol-2-ylmethyl)-[4-(octahydro-indolizin-3-yl)-phenyl]-amine;
Dibenzyl-[4-(octahydro-indolizin-3-yl)-phenyl]-amine;
(*R, R*)-Octahydro-3-[4-(4-pyridinylthio)phenyl]indolizine; and
(*S, S*)-Octahydro-3-[4-(4-pyridinylthio)phenyl]indolizine. .

23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1, 13, 14 or 19.

24. A method for treating a disorder or condition mediated by the histamine H_3 receptor in a subject, said method comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 13 or 19.

25. A method of claim 24, wherein said disorder or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

26. A method for treating a disease or condition modulated by at least one receptor selected from the histamine H_1 receptor and the histamine H_3 receptor, said method comprising (a) administering to a subject a jointly

effective amount of a histamine H_1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, 13, 14, or 19, said method providing a jointly therapeutically effective amount of said compounds.

27. The method of claim 25 wherein the histamine H_1 receptor antagonist and the compound of claim 1, 13, 14, or 19 are present in the same dosage form.

28. A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H_2 receptor and the histamine H_3 receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H_2 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, 13, 14, 19, said method providing a jointly therapeutically effective amount of said compounds.

29. The method of claim 27 wherein the histamine H_2 receptor antagonist and the compound of claim 1 are present in the same dosage form.

30. A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 13, 14, or 19.

31. A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 13, 14, or 19.

32. A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a

subject a therapeutically effective amount of a compound of claim 1, 13, 14, or 19.

33. A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of claim 1, 13, 14, or 19.

34. A method for studying disorders mediated by the histamine H_3 receptor, comprising using an "C- or ^{18}F-labeled compound of claim 1 or 19 as a positron emission tomography (PET) molecular probe.